Cargando…

971. Pharmacokinetic Estimation Analysis of Multi-Dose Regimens of Dalbavancin for Treatment of Osteomyelitis or Bacteremia

BACKGROUND: The management of multi-drug resistant gram-positive infections such as methicillin-resistant Staphylococcus aureus (MRSA) is a complicated task. This is made more difficult when prolonged treatment durations are required, such as for bacteremia, endocarditis, osteomyelitis, or other dee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volk, Cecilia, Hutson, Paul, Rose, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678073/ http://dx.doi.org/10.1093/ofid/ofad500.026

Ejemplares similares

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
por: Rose, Warren E., et al.
Publicado: (2020)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

1563. Population Pharmacokinetics and Pharmacodynamics of Daily and Extended Interval Dalbavancin Dosing Regimens for Salvage Therapy of Staphylococcus aureus Endocarditis: Mechanistic Modeling of Rabbit Infection Data to Support Human Dosing Regimens
por: Farkas, Andras, et al.
Publicado: (2019)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

108. Efficacy of Dalbavancin Compared to Standard of Care for the Treatment of Osteomyelitis: A Retrospective Study
por: Cain, Alexander, et al.
Publicado: (2021)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

971. The Role of Inflammation and Innate Effectors in Passive Immunization for Acinetobacter baumannii Infections
por: Nielsen, Travis B, et al.
Publicado: (2019)

637. Β-Lactam (BL) Antibiotics Promote an IL-1β Response in Patients with Staphylococcus aureus Bacteremia (SaB)
por: Volk, Cecilia, et al.
Publicado: (2018)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

971 Clinical Spectrum of Group B Streptococcol Cellulitis-Adenitis Syndrome
por: Pretorius, Christopher C., et al.
Publicado: (2014)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

971. Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis
por: Wasylyshyn, Anastasia, et al.
Publicado: (2018)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

1247. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients
por: Diaz, Julia Garcia, et al.
Publicado: (2020)

973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
por: Olney, Katie B, et al.
Publicado: (2023)

398 Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures
por: Baldassarre, James, et al.
Publicado: (2014)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review
por: Cooper, Margaret M, et al.
Publicado: (2021)

Italian concerto, BWV 971 Chromatic fantasia and fugue, BWV 903 ; French suites BWV 812 & 813 /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
por: Rappo, Urania, et al.
Publicado: (2018)

Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis
por: Cain, Alexander R, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

1430. The Hidden Costs of Vancomycin Use During the Treatment of Staphylococcus aureus Bacteremia Concurrent with Acute Hematogenous Osteomyelitis
por: Ashley. Copley, Lawson, et al.
Publicado: (2019)

Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report
por: Almangour, Thamer A., et al.
Publicado: (2017)

1427. Treatment of Children with Acute Hematogenous Osteomyelitis and Staphylococcus aureus Bacteremia: Impact of Severity of Illness on Antimicrobial Therapy
por: Copley, Lawson Ashley, et al.
Publicado: (2019)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

225. Dalbavancin Usage in Patients Who Inject Drugs (PWID)
por: Patel, Kaya, et al.
Publicado: (2023)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tnu5l79ct6uqurqgef693fpsin